Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor During Definitive Concurrent Chemoradiotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer: A Prospective Cohort Study

NCT06958614 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT06958614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06958614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor During Definitive Concurrent Chemoradiotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer: A Prospective Cohort Study
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Observational
Overall status
Completed
Start date
September 2, 2019
Completion date
January 30, 2025
Enrollment
213 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

concurrent chemotherapy, conditions influencing health status, stage ii-iii non-small cell lung cancer